Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues

Chinese Journal of Cancer

Volumn 28, Issue 2, 2009, Pages 142-145

  Yang, Guo Fen ^a   Cai, Peng Yu ^a   Li, Xiao Ming ^a   Deng, Hai Xia ^b   He, Wei Peng ^a   Xie, Dan ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Clusterin; Ovarian neoplasms; Prognosis; YKL 40

Indexed keywords

ONCOPROTEIN; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; EPITHELIUM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY;

EPITHELIAL CELLS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 70349498420     PISSN: 1000467X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Walsh JM, Dolan NC, Charney P, et al. Update in women's health [J]. Ann Int Med, 2000, 133(10):808-814.
2. Menon U, Jacobs I[J]. Recent developments in ovarian cancer screening [J]. Curr Opin Obstet Gynaecol, 2000,12(1):39-42.
3. Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40 [J]. J Clin Oncl, 2004, 22(16):3330-3339.
4. Johansen JS, Drivsholm L, Price PA, et al. High serum YKL-40 level in patients with small cell lung cancer is related to early death [J]. Lung Cancer, 2004,46(3):333-340.
5. Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer [J]. Gynecol Oncol, 2007,104(2):435-442.
6. Lau SH, Sham JS, Xie D, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis [J]. Oncogene, 2006,25(8):1242-1250.
7. Yang GF, Li XM, Xie D, et al. Clusterin protein expression and apoptosis in ovarian cancer [J]. Zhong Guo Zhong Liu Lin Chuang, 2007,34(12):674-676.
8. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer [J]. Dan Med Bull, 2006,53(2):172-209.
9. Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? [J]. Cancer Epidemiol Biomarkers Prev, 2006,15(2):194-202.
10. Dehn H, Hogdall EV, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer [J]. Acta Obstec Gynecol Scand, 2003,82(3):287-293.
11. Gronlund B, Hogdall EV, Chiristensen IJ, et al. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA125) [J]. Int J Biol Markers, 2006,21(3):141-148.
12. Malinda KM, Ponce L, Kleinman HK, et al. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells [J]. Exp Cell Res, 1999,250(1):168-173.